- Fucktard   Mar 31, 2011 at 11:16: AM
Fucktard
Well-Known Member
Was reading the NEJM online, and came across a journal article and subsequent letters to the editor on this topic. I will put it (somewhat) in a nutshell for you all, and I am interested in seeing what you all think.
Colchicine has been available in the US as a generic product since the 19th century. Physicians have used it to treat gout for a zillion years. Cochicine has never gone through the FDA process as an "approved" drug. There are many manufacturers of it. Its length of time on the market, success in treatment, and lack of adverse events (few on record and mostly due to human error) lend it as an acceptable treatment for gout, and FMF.
Along comes URL Pharma out of Philadelphia, who does a study on safety/efficacy of their colchicine, which they have named Colcrys. Studies are done, FDA approves the drug. URL is now granted 3 years of exclusivity of Colcrys for gout. Under the Orphan Drug Act, it is granted exclusivity for its use in FMF - Familiar Mediterranean Fever, for SEVEN years. URL then immediately turns around and files suit against every other colchicine manufacturer, getting all other forms taken off of the market, as Colcrys is now the only approved version.
URL also turned around and immediately priced their Colcrys at $4.85 per pill. Colchicine has been available previously for 99 cents per pill.
The director of the FMF clinic in California wrote in and stated that a 50 fold increase would lead to these patients missing doses and the disorder causes debilitating fevers and abdominal pain, which when not controlled with colchicine, will increase physician/ER visits and hospitalizations.
Now what do you think of this? I would imagine that there are some of you that think this is brilliant, that URL deserves to be rewarded for this "hard work." I know there are others, like me, who find this despicable and ridiculous. In these economic times, to turn around and burden payers, patients, Medicaid, Medicare, etc., with a 50X increase in cost on a very old drug is criminal.
Feel free to read what I read - www.nejm.org. You can find these entries under rheumatology, and these are free articles.
Colchicine has been available in the US as a generic product since the 19th century. Physicians have used it to treat gout for a zillion years. Cochicine has never gone through the FDA process as an "approved" drug. There are many manufacturers of it. Its length of time on the market, success in treatment, and lack of adverse events (few on record and mostly due to human error) lend it as an acceptable treatment for gout, and FMF.
Along comes URL Pharma out of Philadelphia, who does a study on safety/efficacy of their colchicine, which they have named Colcrys. Studies are done, FDA approves the drug. URL is now granted 3 years of exclusivity of Colcrys for gout. Under the Orphan Drug Act, it is granted exclusivity for its use in FMF - Familiar Mediterranean Fever, for SEVEN years. URL then immediately turns around and files suit against every other colchicine manufacturer, getting all other forms taken off of the market, as Colcrys is now the only approved version.
URL also turned around and immediately priced their Colcrys at $4.85 per pill. Colchicine has been available previously for 99 cents per pill.
The director of the FMF clinic in California wrote in and stated that a 50 fold increase would lead to these patients missing doses and the disorder causes debilitating fevers and abdominal pain, which when not controlled with colchicine, will increase physician/ER visits and hospitalizations.
Now what do you think of this? I would imagine that there are some of you that think this is brilliant, that URL deserves to be rewarded for this "hard work." I know there are others, like me, who find this despicable and ridiculous. In these economic times, to turn around and burden payers, patients, Medicaid, Medicare, etc., with a 50X increase in cost on a very old drug is criminal.
Feel free to read what I read - www.nejm.org. You can find these entries under rheumatology, and these are free articles.
Last edited: